GlassScriptPhysician profile
Subbarao Mylavarapu
NPI 1659330850
$202,525.54
in general payments reported to CMS, 2019-2025
55 companies · $1,387 in 2025
The $1,387 reported for 2025 was more than what 77% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $89K · 2021: $36K · 2022: $16K · 2023: $15K · 2024: $9,349 · 2025: $1,387.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $11K · Food and Beverage: $7,219 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,600 · Travel and Lodging: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $10,500.00 |
| Food and Beverage | $7,218.59 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,600.00 |
| Travel and Lodging | $1,044.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cathworks, INC. | $103,479.19 | 2019-2021 | |
| Microvention, INC. | $62,250.00 | 2019-2024 | |
| Edwards Lifesciences Corporation | $9,478.25 | 2020-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Shockwave Medical, INC | $6,758.96 | 2023-2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Siemens Medical Solutions USA, INC. | $4,714.87 | 2022 | |
| Cordis US Corp. | $3,555.30 | 2022-2023 | |
| Medtronic, INC. | $2,178.50 | 2021-2025 | Corevalve Evolut R, Micra, Cobalt Dr Mri Surescan |
| Abbott Laboratories | $831.78 | 2019-2025 | Xience Sierra, Aveir, Amplatzer Talisman |
| Novartis Pharmaceuticals Corporation | $818.09 | 2021-2025 | |
| Amgen INC. | $694.26 | 2019-2025 | Repatha, Repatha |
| Abiomed | $587.62 | 2019-2025 | Impella |
| Pfizer INC. | $565.74 | 2019-2025 | |
| Cvrx, INC. | $556.17 | 2022-2025 | Barostim Neo System |
| Janssen Pharmaceuticals, INC | $461.64 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $450.21 | 2019-2025 | Camzyos, Eliquis |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.20 | 2021-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $383.16 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $376.13 | 2019-2025 | Rotapro, Watchman Flx, General - Balloon Catheters |
| Heartflow, INC. | $327.83 | 2020-2024 | Ffrct |
| Alnylam Pharmaceuticals INC. | $278.71 | 2019-2025 | Amvuttra |
| Kestra Medical Technology Services, INC. | $247.62 | 2022-2025 | Assure Wcd |
| Cleerly, INC. | $235.76 | 2024-2025 | Cleerly Ischemia, Cleerly Labs |
| Penumbra, INC. | $234.54 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $210.51 | 2019-2024 | Wainua, Farxiga |
| Merck Sharp & Dohme LLC | $193.08 | 2022-2025 | Verquvo |
| Impulse Dynamics (USA) INC. | $182.64 | 2023-2024 | Optimizer, Optimizer |
| Cardiva Medical, INC. | $180.74 | 2022-2024 | Cardiva Vascade Mvp Vvcs 6-12f, Optowire |
| Biotronik INC. | $176.90 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $167.61 | 2019-2024 | |
| Recor Medical INC | $156.55 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Medtronic Vascular, INC. | $137.20 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $120.85 | 2019-2023 | Opsumit, Uptravi |
| Otsuka America Pharmaceutical, INC. | $120.35 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $105.57 | 2021-2023 | Evkeeza |
| Bardy Diagnostics, INC. | $85.63 | 2019-2022 | |
| Scpharmaceuticals INC. | $77.00 | 2024 | |
| Cmp Pharma, INC. | $72.10 | 2022-2023 | Norliqva, Tadliq, Carospir |
| Amarin Pharma, INC. | $60.35 | 2019-2022 | |
| Cardiovascular Systems INC. | $60.16 | 2019-2020 | |
| Esperion Therapeutics, INC. | $59.02 | 2023-2025 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $48.23 | 2022-2023 | Arcalyst |
| Ge Healthcare | $44.91 | 2023 | |
| Biosense Webster, INC. | $44.23 | 2021 | |
| Zoll Respicardia, INC. | $42.84 | 2024-2025 | Remede System |
| Baxter Healthcare | $42.52 | 2023-2025 | Hillrom - Cardiac Ambulatory Monitor |
| Novo Nordisk INC | $41.05 | 2024 | Wegovy, Ozempic |
| Zoll Circulation INC | $37.80 | 2020 | |
| Chiesi USA, INC. | $36.88 | 2023 | Kengreal |
| Genzyme Corporation | $30.95 | 2024 | |
| Irhythm Technologies, INC. | $27.84 | 2024 | Zio Monitor, Zio Xt Patch |
| Lundbeck LLC | $21.42 | 2019 | |
| Bridgebio Pharma, INC. | $20.69 | 2025 | Attruby |
| Sanofi Pasteur INC. | $16.32 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.30 | 2024 | |
| Z-Medica, LLC | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,125.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subbarao Mylavarapu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.